Prelude Therapeutics, Inc. (PRLD)
5.325
-0.14
(-2.65%)
USD |
NASDAQ |
Aug 31, 13:15
Prelude Therapeutics Shareholders Equity (Quarterly) : 133.73M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 133.73M |
| March 31, 2026 | 60.18M |
| December 31, 2025 | 68.64M |
| September 30, 2025 | 58.53M |
| June 30, 2025 | 75.84M |
| March 31, 2025 | 103.18M |
| December 31, 2024 | 131.46M |
| September 30, 2024 | 156.43M |
| June 30, 2024 | 182.28M |
| March 31, 2024 | 210.73M |
| December 31, 2023 | 237.09M |
| September 30, 2023 | 238.26M |
| June 30, 2023 | 262.06M |
| March 31, 2023 | 175.30M |
| Date | Value |
|---|---|
| December 31, 2022 | 195.44M |
| September 30, 2022 | 217.41M |
| June 30, 2022 | 240.84M |
| March 31, 2022 | 261.81M |
| December 31, 2021 | 285.90M |
| September 30, 2021 | 311.24M |
| June 30, 2021 | 334.36M |
| March 31, 2021 | 356.57M |
| December 31, 2020 | 212.18M |
| September 30, 2020 | 228.31M |
| June 30, 2020 | 27.07M |
| March 31, 2020 | |
| December 31, 2019 | 17.03M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 727.71M |
| Twist Bioscience Corp. | 445.74M |
| Beam Therapeutics, Inc. | 1.067B |
| Revolution Medicines, Inc. | 2.606B |
| Sana Biotechnology, Inc. | 154.57M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 189.36M |
| Total Liabilities (Quarterly) | 55.63M |
| Debt to Equity Ratio | 0.132 |
| Current Ratio | 4.072 |
| Net Debt Paydown Yield | 0.01% |